Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Eli Lilly Partner for Spanish NSCLC Biomarker Study

NEW YORK – Biocartis announced Thursday that it entered into a collaboration with Eli Lilly to study the addition of Biocartis' Idylla platform to a molecular diagnostics workflow.

The study, taking place at hospitals across Spain, will examine how Idylla, a fully automated and cartridge-based real-time PCR system, might contribute to a faster and more comprehensive approach to identifying targetable genetic alterations in non-small cell lung cancer (NSCLC) compared to current clinical workflows.

Eli Lilly is sponsoring the study, whose results will be used to guide and improve community-based diagnostic workflows in the US using Idylla. Biocartis expects to present outcome data in the fall of 2024.

"I am pleased that Lilly shares our commitment to address the need for faster identification of eligible patients for targeted therapy," Biocartis CEO Roger Moody said in a statement. "Despite guidelines and reimbursement, patients, especially those in community hospital settings, continue to receive treatment based on incomplete or untimely biomarker results. Our collaboration with Lilly supports our ambition to deliver results in time for all patients, including those being treated in community-based centers."

In April, Mechelen, Belgium-based Biocartis partnered with Apis Assay Technologies to develop and commercialize Apis' Breast Cancer Subtyping assay on the Idylla platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.